These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12839314)

  • 21. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma.
    Craven D; Kercsmar CM; Myers TR; O'riordan MA; Golonka G; Moore S
    J Pediatr; 2001 Jan; 138(1):51-58. PubMed ID: 11148512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.
    Handley D
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S69-76. PubMed ID: 10452791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.
    Buchwald A; Hochhaus G
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):652-60. PubMed ID: 9877002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma.
    Skoner DP; Greos LS; Kim KT; Roach JM; Parsey M; Baumgartner RA
    Pediatr Pulmonol; 2005 Dec; 40(6):477-86. PubMed ID: 16193496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.
    Nelson HS; Bensch G; Pleskow WW; DiSantostefano R; DeGraw S; Reasner DS; Rollins TE; Rubin PD
    J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):943-52. PubMed ID: 9847435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma.
    Maier G; Rubino C; Hsu R; Grasela T; Baumgartner RA
    Pulm Pharmacol Ther; 2007; 20(5):534-42. PubMed ID: 16891136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.
    Handley DA; Tinkelman D; Noonan M; Rollins TE; Snider ME; Caron J
    J Asthma; 2000 Jun; 37(4):319-27. PubMed ID: 10883742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma.
    Ibe BO; Portugal AM; Raj JU
    Int Arch Allergy Immunol; 2006; 139(3):225-36. PubMed ID: 16446544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
    Ralston ME; Euwema MS; Knecht KR; Ziolkowski TJ; Coakley TA; Cline SM
    J Emerg Med; 2005 Jul; 29(1):29-35. PubMed ID: 15961004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
    Truitt T; Witko J; Halpern M
    Chest; 2003 Jan; 123(1):128-35. PubMed ID: 12527613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?
    Asmus MJ; Hendeles L
    Pharmacotherapy; 2000 Feb; 20(2):123-9. PubMed ID: 10678290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol.
    Costello J
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S61-8. PubMed ID: 10452790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma.
    Cydulka RK; Emerman CL; Muni A
    J Asthma; 2010 Dec; 47(10):1094-100. PubMed ID: 20923385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levalbuterol and racemic albuterol: are there therapeutic differences?
    Ahrens R; Weinberger M
    J Allergy Clin Immunol; 2001 Nov; 108(5):681-4. PubMed ID: 11692088
    [No Abstract]   [Full Text] [Related]  

  • 36. Introduction of a single isomer beta agonist.
    Rau JL
    Respir Care; 2000 Aug; 45(8):962-6. PubMed ID: 10963321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrasting properties of albuterol stereoisomers.
    Page CP; Morley J
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S31-41. PubMed ID: 10452786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical response to levalbuterol.
    Broski SE; Amundson DE
    J Am Osteopath Assoc; 2008 Apr; 108(4):211-3. PubMed ID: 18443029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial.
    Andrews T; McGintee E; Mittal MK; Tyler L; Chew A; Zhang X; Pawlowski N; Zorc JJ
    J Pediatr; 2009 Aug; 155(2):205-10.e1. PubMed ID: 19464028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients.
    Kelly A; Kennedy A; John BM; Duane B; Lemanowicz J; Little J
    Ann Pharmacother; 2013 May; 47(5):644-50. PubMed ID: 23613097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.